Disease · MONDO_0002928

carcinosarcoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. carcinosarcoma. Diseases, record MONDO_0002928. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0002928

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: carcinosarcoma; Open Targets
Open Targets ID: MONDO_0002928; Open Targets
Other names: carcinosarcoma, malignant, malignant mixed Mullerian tumour, malignant mixed mesodermal (mullerian) tumour, mesodermal mixed tumor (morphologic abnormality), mesodermal mixed tumour, mesodermal mixed tumour (morphologic abnormality), mixed mesodermal (mullerian) tumour, mullerian mixed tumor (morphologic abnormality), mullerian mixed tumour, mullerian mixed tumour (morphologic abnormality); Open Targets
Disease Ontology: DOID:4236; Disease Ontology
MeSH: D002296; MeSH
NCI Thesaurus: C34448; NCI Thesaurus
Highest stage of its drugs: Phase 3, for 5 of its 29 drugs, from ClinicalTrials.gov; Open Targets

Drugs29

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
PACLITAXEL	CHEMBL428647	Small molecule	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets
IFOSFAMIDE	CHEMBL1024	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
CISPLATIN	CHEMBL11359	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
FILGRASTIM	CHEMBL1201567	Protein	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
SACITUZUMAB GOVITECAN	CHEMBL3545262	Antibody drug conjugate	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
NIRAPARIB	CHEMBL1094636	Small molecule	Phase 2/3	ClinicalTrials.gov	2	2	2	Drugs and targets
DOSTARLIMAB	CHEMBL4298124	Antibody	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
CARBOPLATIN	CHEMBL1351	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
NIVOLUMAB	CHEMBL2108738	Antibody	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
OLAPARIB	CHEMBL521686	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets

1 to 10 of 29

See all 29 drugs

Targets58

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
KDR	Vascular endothelial growth factor receptor	4	Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/3791	Drugs and targets
PDCD1	Programmed cell death protein 1	4	Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor	Phase 2/3	https://conductscience.org/library/genes/5133	Drugs and targets
PARP1	PARP 1, 2 and 3	3	PARP 1, 2 and 3 inhibitor; Poly [ADP-ribose] polymerase-1 inhibitor	Phase 2/3	https://conductscience.org/library/genes/142	Drugs and targets
PARP2	PARP 1, 2 and 3	3	PARP 1, 2 and 3 inhibitor; Poly [ADP-ribose] polymerase 2 inhibitor	Phase 2/3	https://conductscience.org/library/genes/10038	Drugs and targets
CSF1R	Macrophage colony-stimulating factor 1 receptor	2	Macrophage colony stimulating factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/1436	Drugs and targets
ERBB2	Receptor tyrosine-protein kinase erbB-2	2	Receptor protein-tyrosine kinase erbB-2 inhibitor	Phase 2	https://conductscience.org/library/genes/2064	Drugs and targets
FLT1	Vascular endothelial growth factor receptor	2	Vascular endothelial growth factor receptor 1 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/2321	Drugs and targets
FLT3	Receptor-type tyrosine-protein kinase FLT3	2	Tyrosine-protein kinase receptor FLT3 inhibitor	Phase 2	https://conductscience.org/library/genes/2322	Drugs and targets
FLT4	Vascular endothelial growth factor receptor	2	Vascular endothelial growth factor receptor 3 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/2324	Drugs and targets
KIT	Mast/stem cell growth factor receptor Kit	2	Stem cell growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/3815	Drugs and targets

1 to 10 of 58

See all 58 targets

Trials19

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03783949	European Trial on Enhanced DNA Repair Inhibition in Ovarian Cancer	Phase 2	122	2025-06-11	Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma	CARBOPLATIN, GANETESPIB, GEMCITABINE, NIRAPARIB, PACLITAXEL	Its record names the disease	ClinicalTrials.gov
NCT03395080	A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer or Carcinosarcoma	Phase 2	111	2023-06-09	Endometrial Cancer, Uterine Cancer, Ovarian Cancer, Carcinosarcoma	DKN-01, PACLITAXEL	Its record names the disease	ClinicalTrials.gov
NCT00478426	Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer	Phase 2	34	2020-02-17	Endometrial Adenocarcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Serous Adenocarcinoma, Recurrent Uterine Corpus Carcinoma, Stage IVA Uterine Corpus Cancer AJCC v7, Stage IVB Uterine Corpus Cancer AJCC v7, Uterine Carcinosarcoma, Uterine Corpus Carcinosarcoma	SUNITINIB MALATE	Its record names the disease	ClinicalTrials.gov
NCT04513665	ZW25 in Women With Endometrial Cancers	Phase 2	16	2024-10-21	Endometrial Cancer, Carcinosarcoma	ZANIDATAMAB	Its record names the disease	ClinicalTrials.gov
NCT01061606	Temsirolimus in Treating Patients With Recurrent or Persistent Cancer of the Uterus	Phase 2	8	2016-11-09	Recurrent Uterine Sarcoma, Uterine Carcinosarcoma	TEMSIROLIMUS	Its record names the disease	ClinicalTrials.gov
NCT06486441	Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)	Phase 3	640		Endometrial Cancer	SACITUZUMAB GOVITECAN	Its record names the disease	ClinicalTrials.gov
NCT00002546	Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Cancer of the Uterus	Phase 3	216		Sarcoma	CISPLATIN, IFOSFAMIDE	Its record names the disease	ClinicalTrials.gov
NCT04065269	ATr Inhibitor in Combination With Olaparib/Durvalumab (MEDI4736) in Gynaecological Cancers With ARId1A Loss or no Loss	Phase 2	174		Gynaecological Cancers	CERALASERTIB, DURVALUMAB, OLAPARIB	Its record names the disease	ClinicalTrials.gov
NCT00003128	Ifosfamide With or Without Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cancer of the Uterus	Phase 3	166		Sarcoma	FILGRASTIM, IFOSFAMIDE, PACLITAXEL	Its record names the disease	ClinicalTrials.gov
NCT03651206	Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib	Phase 2/3	138		Ovarian Carcinosarcoma, Endometrial Carcinosarcoma	DOSTARLIMAB, NIRAPARIB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 19

See all 19 trials

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials21

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
25341582	RESULT	1	PubMed
24882554	RESULT	1	PubMed
23410977	RESULT	1	PubMed
23397080	RESULT	1	PubMed
18755503	RESULT	1	PubMed
18378136	RESULT	1	PubMed
17936342	RESULT	1	PubMed
17822748	RESULT	2	PubMed
17395252	RESULT	1	PubMed
17290061	RESULT	2	PubMed

1 to 10 of 21

See all 21 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0002928

GET https://conductscience.org/api/diseases/v1/MONDO_0002928/drugs?page=2

API reference For AI assistants